Meclizine, sold under the brand name of Bonine .
It is an antihistamine used to treat motion sickness and vertigo.
A first-generation antihistamine (nonselective H1 antagonist) of the piperazine class.
It is taken by mouth.
It effects generally begin in an hour after presentation and last for up to a day.
Administered by mouth, under the tongue, in the administered by cheek
Metabolism by Liver
Elimination half-life 6 hours
Side effects include sleepiness and dry mouth.
Use in pregnancy appears safe but has not been well studied.
Use in breastfeeding is of unclear safety.
Its mechanisms of action in part due to by anticholinergic and antihistamine properties.
Safety and efficacy in children younger than twelve years of age has not been established.
In the elderly there is increased risk of confusion and amnesia.
Effective in inhibiting nausea, vomiting, and dizziness caused by motion sickness.
It is used to treat motion sickness or vertigo such as in those with Meniere’s disease.
Common side effects: drowsiness, dry mouth, and tiredness may occur.
Has fewer dry mouth side effects than transdermal scopolamine.
Anticholinergic agents such as meclizine may cause confusion or aggravate symptoms in those with dementia in the elderly.
It should be used with caution in the elderly.
It is an antagonist at the H1 receptors.
It has anticholinergic, central nervous system depressant, and local anesthetic effects.
It depresses labyrinth excitability and vestibular stimulation.
It may affect the medullary chemoreceptor trigger zone to inhibit nausea.
It likely affects many sensory mechanisms related to self-motion.
It is a dopamine antagonist at D1-like and D2-like receptors.
Half-life of six hours.
It is sometimes combined with opioids.